Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. Range

This publication has 15 references indexed in Scilit:

• Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)
  The Prostate, 2001
• Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer
  The Prostate, 2000
• NONPALPABLE STAGE T1C PROSTATE CANCER: PREDICTION OF INSIGNIFICANT DISEASE USING FREE/TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS AND NEEDLE BIOPSY FINDINGS
  Journal of Urology, 1998
• USE OF LOWER PROSTATE SPECIFIC ANTIGEN CUTOFFS FOR PROSTATE CANCER SCREENING IN BLACK AND WHITE MEN
  Journal of Urology, 1998
• Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
  JAMA, 1998
• THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCER
  Journal of Urology, 1998
• Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis
  Urology, 1997
• Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination
  JAMA, 1997
• Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
  New England Journal of Medicine, 1991
• Enzymatic activity of prostate‐specific antigen and its reactions with extracellular serine proteinase inhibitors
  European Journal of Biochemistry, 1990